Trial Profile
A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2023
Price :
$35
*
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use; Registrational
- Sponsors GE Healthcare
- 19 Oct 2020 Results evaluating novel Ab-PET based quantitative measure using data from four trials (NCT01208675, NCT00106899, NCT01165554 and NCT02090855) published in the Neurology
- 30 Jun 2014 The CHMP of the EMA provided a positive opinion on the MAA for Vizamyl indicated for PET imaging of the brain to estimate beta amyloid neuritic plaque density in patients evaluated for Alzheimer's disease.
- 06 Nov 2013 New trial record